

Market wrap Dec. 29, 2021

## Domestic bourses end in red; healthcare stocks rally as Omicron cases rise..

Index	Today's Close	Prev. close	Change	% change	Open	High	Low
Sensex	57,806.49	57,897.48	90.99	0.16	57,892.31	58,097.07	57,684.58
Nifty	17,213.60	17,233.25	19.65	0.11	17,220.10	17,285.95	17,176.55

- 1) Indian benchmark indices ended in red on Wednesday.
- 2) The Sensex was down by 90.99 points or 0.16 percent to end at levels of 57,806.49. Among the Sensex 30 stocks, Sun Pharma was up by 2.5 percent. IndusInd Bank and Dr.Reddy's were the other major Sensex gainers, up around 1.5 per cent each. Bajaj Finserv and Titan were the other notable gainers. On the other hand, SBI was down by 2 per cent. ITC, NTPC, Tech Mahindra, Axis Bank, Tata Steel and Kotak Bank were the other major losers.
- 3) Nifty was down by 19.65 points or 0.11 percent to end at levels of 17,213.60.
- 4) The broader markets ended in positive terrain today. The BSE Midcap index was up by 0.1 percent while the BSE Smallcap index was up by 0.5 percent.

#### Sectors and stocks

- 1) Shares of Sun Pharma were up by 2.5 per cent, after the company announced its plans to set-up an end-to-end manufacturing plant in Andhra Pradesh. Meanwhile, pharma shares as a sector was one of the top performer. The BSE Healthcare index strengthened by 1.6 per cent. A slew of pharma firm have launched a generic version of Molnupiravir in India post approval for emergency use authorisation from Drugs Controller General of India (DCGI) in the backdrop of the Omicron threat.
- 2) Shares of Supriya Lifescience (SLL) rallied by 20 per cent to Rs. 468.40 on the BSE in Wednesday's intra-day trade, after the company made a strong stock market debut on Tuesday. With today's rally, the stock of the pharmaceuticals company has rallied by 71 per cent against its issue price of Rs. 274 per share. Supriya Lifescience (SLL) has made a strong market debut, with its shares listing at Rs. 425, a 55 per cent premium over its issue price of Rs. 274 per share on the BSE. The stock has opened at Rs. 421, a 54 per cent higher against its issue price on the National Stock Exchange (NSE). SLL is one of the key Indian manufacturers and suppliers of active pharmaceuticals ingredients (APIs) had garnered investors' interest on the back of strong financials and attractive valuations. The IPO had received a strong response, which was subscribed 71.51 times on back of robust subscription of individual investors. Retail investors bid 56 times the reserved portion, and non-institutional investors' portion was subscribed 161 times, whereas qualified institutional investors bid for 31.83 times. We had recommended "SUBSCRIBE" to the issue.
- 3) Shares of Balrampur Chini Mills (BCML) were up 5 per cent at Rs. 359.90 on the BSE in Wednesday's intra-day trade, on the back of heavy volumes. The stock has rallied 17 per cent in past six trading days, after the company announced that it had received total orders of 157,100 kilo litres for supplying ethanol to both public sector and private sector oil marketing companies (OMCs). On December 20, 2021, BCML announced that the company had participated in tenders floated by public sector OMCs for supplying ethanol for the period starting December 1, 2021 till November 30, 2022 at their various locations across the country. "Accordingly, we have been allocated 139,100 Kilo litres from our various manufacturing units at Uttar Pradesh," the company said. In addition to the aforesaid, BCML was in receipt of an order to supply 18,000 kilo litres of ethanol to private sector OMCs. Hence, the company received total orders of 157,100 kilo litres for supplying ethanol to both public sector and private sector OMCs, it had said. Meanwhile, BCML has announced large capex of around Rs 993 crore over FY2022-FY2023 towards distillery capacity expansion, modernisation of plants/debottlenecking and setting up of refineries. For funding the said capex, Rs 500-crore debt (partially under interest subvention) is planned to be availed.



4) Shares of C E Info Systems (MapmyIndia) hit a new high of Rs. 1,774.80, on rallying 10 per cent on the BSE in Wednesday's intra-day trade. The stock has rallied by 22 per cent in last two trading sessions after having made a strong debut last week. With the past two-day rally, MapmyIndia now commands a whopping 72 per cent premium to its issue price of Rs 1,033 per share on the BSE. The company had made its stock market debut on December 21, 2021. MapmyIndia is India's leading provider of advanced digital maps, geospatial software and location based IoT technologies. It is a leader in the B2B and B2B2C market, serving over 500 enterprise customers across 3 major categories - corporate, automotive and government. Some of the marquee names include PhonePe, Flipkart, Yulu, HDFC Bank, Airtel, Hyundai, Avis, Safexpress, GST Network, etc.

#### Key recent major developments...

- 1) FIIs sold equities worth Rs. 975.23 Crore on 29th Dec. 2021. Month till date, FIIs have sold equities worth Rs. 35,082.66 Crore against selling of Rs. 39,901.92 Crore in November 2021.
- 2) Though the economy has steadily gained momentum and remained resilient since the second quarter of the current fiscal, the Omicron variant of coronavirus remains the major challenge along with rising inflation pressures, says the Reserve Bank in its second financial stability report. In the foreword to the report released on Wednesday, RBI Governor Shaktikanta Das notes that after the destructive second wave in April-May 2021, the growth outlook has progressively improved, though there are headwinds from global developments and more recently from the Omicron virus. A stronger and sustainable recovery hinges on the revival of private investment and shoring up private consumption, which unfortunately still remain below their pre-pandemic levels, he notes.
- 3) Mumbai reported 2,510 new COVID-19 cases in the last 24 hours which is a matter of concern.
- 4) India has approved Merck's Covid-19 pill and two more vaccines for emergency use as the country is witnessing possible spike in coronavirus cases due to the rapidly spreading Omicron variant. Molnupiravir will be manufactured in India by 13 companies for restricted use under emergency situation for treatment of adult patients with Covid-19, said Health Minister Mansukh Mandaviya on Tuesday. Merck's anti-viral pill molnupiravir was authorised by the United States last week for certain high-risk adult patients and has been shown to reduce hospitalisations and deaths by around 30 per cent in a clinical trial.
- 5) Delhi Chief Minister Arvind Kejriwal on Tuesday declared a 'yellow alert' led by spike in COVID-19 cases following the emergence of Omicron variant. As a result schools, colleges, cinemas and gyms will remain closed, shops dealing in non-essential items will open on odd-even basis, and metro trains and buses will run with 50 per cent of seating capacity in the city. In accordance with 'Level-1' alert under the graded response action plan (GRAP), there would be night curfew between 10 pm and 5 am and private offices will function with physical attendance of 50 per cent of the staff, barring essential categories. Marriages and funerals will be allowed attendance of 20 people while all other types of gathering related to social, political, cultural, religious and festival events will be prohibited under the 'yellow alert' that came into force with immediate effect. Shops of non-essential goods and services in markets and malls can open based on odd-even formula from 10 AM to 8 PM. Restaurants will be permitted with 50 per cent of capacity from 8 am to 10 pm while bars can also operate with the same capacity, but from 12 noon to 10 pm. The new restrictions follow the national capital's biggest single-day spike in infections in over six months on Monday when 331 new cases were reported with a positivity rate of 0.67 per cent.
- 6) The Union Home Ministry on December 27, 2021 issued guidelines for COVID-19 vaccination of children aged 15-18 years and for the administration of booster dose to healthcare, frontline workers, and senior citizens with comorbidity. "For those Health Care Workers (HCWs) & Frontline Workers (FLWs) who have received two doses, another dose of COVID-19 vaccine would be provided from January 10," the ministry said in its guidelines. "The prioritization & sequencing of this precaution dose would be based on the completion of 9 months from the date of administration of 2nd dose reads the guidelines," it said. Based on doctor's advive, all persons aged 60 years and above with comorbidities who have received two doses of Covid vaccine will be provided with a precaution dose from January 10, 2022.
- 7) The Centre earlier has advised states and UTs to not let their guard down and maintain their preparedness for fighting Covid in view of the new variant Omicron. Union Health Secretary Rajesh Bhushan reviewed the public health preparedness of the states for fighting Covid and the Omicron variant along with progress of vaccination with Health Secretaries of states and UTs. He highlighted the trajectory of Covid and brought attention to emerging evidence on the Omicron variant of Covid driving the growing number of cases worldwide.



- 8) Union Transport Minister Nitin Gadkari said on December 27 that he has advised automobile manufacturers in India to start making Flex Fuel Vehicles (FFV) and Flex Fuel Strong Hybrid Electric Vehicles (FFV-SHEV) in compliance with BS-6 Norms in a time-bound manner within a period of six months. This move, he said, will drastically reduce greenhouse gas emissions from vehicles on a well-to-wheel basis and added that by drastically reducing greenhouse gas emissions from vehicles, this move will help India comply with its commitment made at COP26 to reduce the total projected carbon emissions by one billion tonnes by 2030.
- 9) Property sale registrations in Mumbai (MCGM region) crossed the 100,000 mark for the first time in a decade, compared to the earlier decade-high at 80,746 units in 2018. Mumbai recorded property sale registrations of 7,582 units in November, an 18% decline year-on-year compared to the corresponding month last year, when the stamp duty rate was reduced to 2%. Sequentially, property registrations fell by 12%. In October 2021, the city had recorded a decadal best October month property sale registration, at 8,576 units.
- 10) Earlier, the Union Cabinet approved a production linked incentive (PLI) scheme for semiconductor and display board production in the country, I&B Minister Anurag Thakur said. The scheme envisages investment of Rs. 76,000 Crore in semiconductor production over the next 5-6 years, he said.

The programme aims to provide attractive incentive support to companies/consortia that are engaged in Silicon Semiconductor Fabs, Display Fabs, Compound Semiconductors/Silicon Photonics/Sensors (including MEMS) Fabs, Semiconductor Packaging (ATMP / OSAT), Semiconductor Design. The programme will usher in a new era in electronics manufacturing by providing a globally competitive incentive package to companies in semiconductors and display manufacturing as well as design, said government while adding that semiconductors and displays are the foundation of modern electronics driving the next phase of digital transformation under Industry 4.0.

- 11) The Indian economy "continues to forge ahead, emerging out of shackles of pandemic," but the rise of the Omicron variant has emerged as the biggest risk factor, said the state of the economy report released with the December bulletin of the Reserve Bank of India (RBI) on Wednesday. The Indian economy bounced back strongly in the second quarter, as the gross domestic product (GDP) surpassed its pre-pandemic levels, and inflation broadly remained under the 6 per cent range, the upper band of the tolerance range of the RBI. The RBI's medium-term target is to keep retail inflation at 4 per cent. In November, the retail inflation came at 4.91 per cent, but wholesale price index (WPI), which it no longer targets, came at a 12 year high of 14.23 per cent.
  - "A host of incoming high frequency indicators are looking upbeat and consumer confidence is gradually returning. Aggregate demand conditions point to sustained recovery, albeit, with some signs of sequential moderation," the report said.

# Global markets

- 1) Asian peer indices ended on a mixed note today. European equities also started trading on a similar note.
- 2) Globally, there are concerns over Omicron in European countries and US. Lockdowns have been too imposed in various European countries.
- 3) China is redoubling efforts to control new virus outbreaks with a lockdown of the 13 million residents of the northern city of Xi'an following a spike in COVID-19 cases. The measure comes just weeks before the country hosts the Winter Olympics in Beijing, roughly 1,000 kilometers (6210 miles) to the west. There was no word on whether the virus was the newly surging omicron variant or the delta variant. China has recorded just seven omicron cases four in the southern manufacturing center of Guangzhou, two in the southern city of Changsha and one in the northern port of Tianjin.
- 4) Last week, The Bank of England (BoE) on Thursday became the first major central bank to raise interest rates since the Covid- 19 pandemic era set in. The central bank resorted to rate hike owing to rising inflation led by high energy costs, labor shortages and other factors. The BoE had earlier maintained that price pressures were transitory and likely to pass in the next few months. Earlier, The Federal Reserve said it would end its pandemic-era bond purchases in March and pave the way for three quarter-percentage-point interest rate hikes by the end of 2022 as the economy nears full employment and the U.S. central bank copes with a surge of inflation. "The economy no longer needs increasing amounts of policy support," Fed Chair Jerome Powell said in a news conference in which he contrasted the near-depression conditions at the onset of the coronavirus pandemic in 2020 with today's environment of rising prices and wages and rapid improvement in the job market. The pace of inflation is uncomfortably high, he said after the end of the Fed's latest two-day policy meeting, and "in my view, we are making rapid progress toward maximum employment," a combination of circumstances that has now convinced all



Fed officials, even the most dovish, that it is time to exit more fully the pandemic policies put in place two years ago.

5) US consumer prices rose last month at the fastest annual pace in nearly 40 years as the consumer price index increased 6.8 percent in November 2021 from November 2020, according to Labor Department data released Friday. Fast increase in inflation and persistent inflation will erode the value of money which pressurise the Federal Reserve to tighten policy. The widely followed inflation gauge rose 0.8% from October, exceeding forecasts and extending a trend of sizable increases that began earlier this year.

# Ajcon Global's observations and view

- 1) Indian benchmark indices ended in red amidst fears of increasing COVID-19 cases domestically and few states have also announced night curfew. Delhi and Mumbai have witnessed significant spike in COVID-19 cases.
- 2) There are concerns like increasing COVID-19 cases led by Omicron variant. Globally, some European countries are already under lockdown ahead of New Year. In addition, hawkish stance of global central banks have already dented sentiments. In addition, there are headwinds like global inflation, valuation concerns and strengthening of US dollar.
- 3) Before the significant correction earlier, the sentiments were upbeat led by RBI's accommodative stance in its Monetary Policy, recent fall in crude oil prices, good GDP data, robust GST collections, strong manufacturing PMI, good Q2FY22 earnings season and management commentary, good economic activity witnessed in the festive season of Navratri and Diwali and good spike in retail participation from Tier II and Tier III cities as people have become more financial literate in COVID-19 crisis.
- 4) There is a strong line up of IPOs. We suggest investors to be careful about the forthcoming IPOs and understand the fundamentals before riding the boom based on risk reward profile. However, IPOs of sectors in limelight like E-Commerce, Insurance, Digital, Speciality chemicals, Companies business model suited to new age, companies having business model which caters to the demands of Electric Vehicles would always gain maximum attention. However, investors have to be careful with expensive IPOs.
- 5) It is advisable to stay away from companies which have ran ahead of fundamentals and valued beyond logic. It would be prudent to stay with quality names at decent valuations in uncertain times. It is advisable for investors to stick to defensives for some time and also look out for stock specific opportunities considering growth outlook and management pedigree. Always remember, corrections in a bull market will keep markets healthy. Investors will continue to track key expectations of different stakeholder groups from upcoming Budget 2022-23, global cues like COVID-19 cases led by the Omicron variant across the globe, global inflation data, oil price movement and developments in China.



#### Disclaimer

Ajcon Global Services Limited is a fully integrated investment banking, merchant banking, corporate advisory, stock broking, commodity and currency broking. Ajcon Global Services Limited research analysts responsible for the preparation of the research report may interact with trading desk personnel, sales personnel and other parties for gathering, applying and interpreting information.

Ajcon Global Services Limited is a SEBI registered Research Analyst entity bearing registration Number INH000001170 under SEBI (Research Analysts) Regulations, 2014.

Individuals employed as research analyst by Ajcon Global Services Limited or their associates are not allowed to deal or trade in securities that the research analyst recommends within thirty days before and within five days after the publication of a research report as prescribed under SEBI Research Analyst Regulations.

Subject to the restrictions mentioned in above paragraph, We and our affliates, officers, directors, employees and their relative may: (a) from time to time, have long or short positions acting as a principal in, and buy or sell the securities or derivatives thereof, of Company mentioned herein or (b) be engaged in any other transaction involving such securities and earn brokerage.

Ajcon Global Services Limited or its associates may have commercial transactions with the Company mentioned in the research report with respect to advisory services.

The information and opinions in this report have been prepared by Ajcon Global Services Limited and are subject to change without any notice. The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of Ajcon Global Services Limited While we would endeavour to update the information herein on a reasonable basis, Ajcon Global Services Limited is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent Aicon Global Services Limited from doing so. This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. Ajcon Global Services Limited will not treat recipients as customers by virtue of their receiving this report. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. Ajcon Global Services Limited accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this report. Past performance is not necessarily a quide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forwardlooking statements are not predictions and may be subject to change without notice. Ajcon Global Services Limited or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

Ajcon Global Services Limited encourages independence in research report preparation and strives to minimize conflict in preparation of research report. Ajcon Global Services Limited or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither Ajcon Global Services Limited nor Research Analysts have any material conflict of interest at the time of publication of this report.

It is confirmed that Akash Jain – MBA (Financial Markets) or any other Research Analysts of this report has not received any compensation from the company mentioned in the report in the preceding twelve months. Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

Ajcon Global Services Limited or its subsidiaries collectively or Directors including their relatives, Research Analysts, do not own 1% or more of the equity securities of the Company mentioned in the report as of the last day of the month preceding the publication of the research report.



It is confirmed that Akash Jain – MBA (Financial Markets) research analyst or any other Research Analysts of Ajcon Global do not serve as an officer, director or employee of the companies mentioned in the report.

Ajcon Global Services Limited may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report.

Neither the Research Analysts nor Ajcon Global Services Limited have been engaged in market making activity for the companies mentioned in the report.

We submit that no material disciplinary action has been taken on Ajcon Global Services Limited by any Regulatory Authority impacting Equity Research Analysis activities.

# **Analyst Certification**

I, Akash Jain MBA (Financial Markets), research analyst, author and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. I also certify that no part of compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view (s) in this report.

## For research related queries contact:

Mr. Akash Jain - Vice President (Research) at, research@ajcon.net, akash@ajcon.net

CIN: L74140MH1986PLC041941

SEBI registration Number: INH000001170 as per SEBI (Research Analysts) Regulations, 2014.

Website: www.ajcononline.com

## Registered and Corporate office

408 - (4<sup>th</sup> Floor), Express Zone, "A" Wing, Cello – Sonal Realty, Near Oberoi Mall and Patel's, Western Express Highway, Goregaon (East), Mumbai – 400063. Tel: 91-22-67160400, Fax: 022-28722062